Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Is disease flare a problem?

C Mahler1

  • 1Department of Endocrinology, AZ Middelheim, Antwerp, Belgium.

Cancer
|December 15, 1993
PubMed
Summary
This summary is machine-generated.

Luteinizing hormone-releasing hormone (LHRH) analogs can cause a temporary testosterone surge in advanced prostate cancer patients, potentially worsening symptoms. Flare prevention is crucial when using LHRH analogs alone.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety, feasibility, and technical success of percutaneous cryoablation to treat vascular anomalies of the extremities.

Clinical radiology·2025
Same author

Paediatric sclerotherapy of vascular anomalies of the hand and digits.

Clinical radiology·2025
Same author

The effect of buzzy®, DistrACTION® cards on reducing pediatric pain and fear during blood collection in the rheumatology polyclinic: A randomized controlled trial.

Journal of pediatric nursing·2023
Same author

Opening up a tailored tutor qualification program for medical students to other healthcare students - a mixed-method study.

BMC medical education·2022
Same author

Failure of total hypophysectomy to remove intrasellar microadenoma in cushing's disease.

Endocrine pathology·2020
Same author

Attitudes towards interprofessional collaboration in young healthcare professionals.

Journal of interprofessional care·2019
Same journal

Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer.

Cancer·2026
Same journal

Proliferative ecotype determines lethal prognosis and therapeutic benefit in urothelial carcinoma.

Cancer·2026
Same journal

Reply to "Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer".

Cancer·2026
Same journal

Pediatric cancer survival in the United States from 2001 to 2021.

Cancer·2026
Same journal

Updates on intratumoral therapies in melanoma.

Cancer·2026
Same journal

Correction to "Scientific highlights and perspectives from the International Inflammatory Breast Cancer Symposium 2025".

Cancer·2026
See all related articles

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Luteinizing hormone-releasing hormone (LHRH) analogs are used for advanced prostate cancer.
  • Initial administration can cause a transient rise in luteinizing hormone (LH) and testosterone levels.
  • This surge, known as the 'flare phenomenon,' may exacerbate cancer symptoms.

Purpose of the Study:

  • To clarify the definition and incidence of the LHRH analog flare phenomenon.
  • To highlight the distinction between clinical and biochemical flares.
  • To emphasize the importance of flare prevention in prostate cancer therapy.

Main Methods:

  • Review of existing literature on LHRH analog therapy for prostate cancer.
  • Analysis of reported incidences and definitions of the flare phenomenon.

Related Experiment Videos

  • Discussion of clinical and biochemical manifestations of the flare.

    • Main Results:

    • The flare phenomenon is characterized by a transient increase in LH and testosterone levels.
    • Reported incidence varies (4-33%) due to inconsistent definitions.
    • Distinction made between clinical flare (symptom exacerbation) and biochemical flare (hormonal changes).

    Conclusions:

    • A clear definition differentiating clinical and biochemical flares is needed.
    • The impact of the flare phenomenon on long-term treatment outcomes remains unclear.
    • Flare prevention is recommended when LHRH analogs are used as monotherapy for advanced prostate cancer.